Skip to content
Disclosery

Bain Capital Life Sciences Investors, LLC

Follow

13F filer, CIK 1703031, Boston, MA

Bain Capital Life Sciences Investors, LLC reported $1,682,021,456 across 21 holdings for the quarter ended 2026-06-30, in a 13F-HR filed 2026-08-14. Its ten largest share positions make up 87.85% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001193125-26-350470

Period
2026-06-30
Reported value
$1.68B
Holdings
21
Top 10 weight
87.85%
New
2
Sold out
1

Part of the filer group Bain Capital Life Sciences Investors, LLC

How groups are built

Largest buys vs the previous quarter

SecurityShares changeApprox. value
KLRAnew+22,583,268$498M
ALKSadded+1,327,938$69.6M
COAGnew+1,650,000$60.6M
CABAadded+7,564,320$23.5M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
NAMSreduced-3,500,000-$119M
HTFLreduced-2,000,000-$58.7M
CNTAexited-635,000-$25.2M
OLMAreduced-387,989-$4.85M
ANNXreduced-774,943-$4.42M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q2 2026

Share positions as resolved from 13F-HR 0001193125-26-350470, largest first. % of portfolio is the value over $1,682,021,456, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
KLRAKAILERA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 22,583,268 shares 22,583,268$498M29.58%newTimeline
HTFLHEARTFLOW INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 12,448,158 shares; 2025Q4: 12,448,158 shares; 2026Q1: 10,448,158 shares; 2026Q2: 8,448,158 shares 8,448,158$248M14.74%-2,000,000Timeline
NAMSNEWAMSTERDAM PHARMA COMPANYQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 10,473,913 shares; 2024Q4: 10,719,110 shares; 2025Q1: 10,719,110 shares; 2025Q2: 10,719,110 shares; 2025Q3: 10,719,110 shares; 2025Q4: 7,306,566 shares; 2026Q1: 7,306,566 shares; 2026Q2: 3,806,566 shares 3,806,566$129M7.67%-3,500,000Timeline
SVRASAVARA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 14,565,457 shares; 2024Q4: 14,565,457 shares; 2025Q1: 17,600,621 shares; 2025Q2: 17,600,621 shares; 2025Q3: 17,600,621 shares; 2025Q4: 17,600,621 shares; 2026Q1: 17,600,621 shares; 2026Q2: 17,600,621 shares 17,600,621$108M6.45%0Timeline
ALKSALKERMES PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 610,000 shares; 2026Q2: 1,937,938 shares 1,937,938$102M6.04%+1,327,938Timeline
SLDBSOLID BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 4,034,582 shares; 2024Q4: 4,034,582 shares; 2025Q1: 7,911,669 shares; 2025Q2: 7,911,669 shares; 2025Q3: 7,911,669 shares; 2025Q4: 7,911,669 shares; 2026Q1: 9,808,819 shares; 2026Q2: 9,808,819 shares 9,808,819$98M5.83%0Timeline
PHVSPHARVARIS N VQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 3,303,381 shares; 2024Q4: 3,303,381 shares; 2025Q1: 3,303,381 shares; 2025Q2: 3,303,381 shares; 2025Q3: 3,181,275 shares; 2025Q4: 2,802,081 shares; 2026Q1: 2,675,509 shares; 2026Q2: 2,675,509 shares 2,675,509$92.5M5.5%0Timeline
OLMAOLEMA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: 7,470,214 shares; 2025Q1: 6,843,954 shares; 2025Q2: 6,843,954 shares; 2025Q3: 6,843,954 shares; 2025Q4: 8,508,641 shares; 2026Q1: 7,473,238 shares; 2026Q2: 7,085,249 shares 7,085,249$88.6M5.27%-387,989Timeline
COAGHEMAB THERAPEUTICS HLDGS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 1,650,000 shares 1,650,000$60.6M3.6%newTimeline
CABACABALETTA BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 2,760,888 shares; 2024Q4: 2,760,888 shares; 2025Q1: 2,760,888 shares; 2025Q2: 9,677,125 shares; 2025Q3: 9,677,125 shares; 2025Q4: 9,677,125 shares; 2026Q1: 9,677,125 shares; 2026Q2: 17,241,445 shares 17,241,445$53.6M3.19%+7,564,320Timeline
XFORX4 PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 563,859 shares; 2025Q3: 2,436,588 shares; 2025Q4: 7,967,454 shares; 2026Q1: 7,967,454 shares; 2026Q2: 7,967,454 shares 7,967,454$37.2M2.21%0Timeline
DNTHDIANTHUS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 3,013,423 shares; 2024Q4: 2,689,707 shares; 2025Q1: 2,689,707 shares; 2025Q2: 2,482,250 shares; 2025Q3: 1,315,892 shares; 2025Q4: 743,592 shares; 2026Q1: 362,470 shares; 2026Q2: 362,470 shares 362,470$35.3M2.1%0Timeline
CCCCC4 THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 1,111,910 shares; 2024Q4: 1,111,910 shares; 2025Q1: 1,111,910 shares; 2025Q2: 1,111,910 shares; 2025Q3: 1,111,910 shares; 2025Q4: 7,171,910 shares; 2026Q1: 7,171,910 shares; 2026Q2: 7,171,910 shares 7,171,910$33.5M1.99%0Timeline
KYTXKYVERNA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 3,368,370 shares; 2024Q4: 3,368,370 shares; 2025Q1: 3,368,370 shares; 2025Q2: 3,368,370 shares; 2025Q3: 3,368,370 shares; 2025Q4: 3,110,000 shares; 2026Q1: 3,110,000 shares; 2026Q2: 2,885,000 shares 2,885,000$25.7M1.53%-225,000Timeline
ANNXANNEXON INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 8,449,748 shares; 2024Q4: 5,249,069 shares; 2025Q1: 5,249,069 shares; 2025Q2: 5,249,069 shares; 2025Q3: 5,249,069 shares; 2025Q4: 5,249,069 shares; 2026Q1: 5,212,674 shares; 2026Q2: 4,437,731 shares 4,437,731$25.3M1.51%-774,943Timeline
RPIDRAPID MICRO BIOSYSTEMS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 8,434,560 shares; 2024Q4: 8,434,560 shares; 2025Q1: 8,434,560 shares; 2025Q2: 8,434,560 shares; 2025Q3: 8,434,560 shares; 2025Q4: 8,434,560 shares; 2026Q1: 8,434,560 shares; 2026Q2: 8,434,560 shares 8,434,560$14.6M0.87%0Timeline
IRONDISC MEDICINE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 1,795,735 shares; 2024Q4: 983,500 shares; 2025Q1: 983,500 shares; 2025Q2: 583,500 shares; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 141,234 shares; 2026Q2: 141,234 shares 141,234$10.3M0.61%0Timeline
AVIRATEA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 2,485,638 shares; 2024Q4: 2,485,638 shares; 2025Q1: 2,485,638 shares; 2025Q2: 2,485,638 shares; 2025Q3: 2,485,638 shares; 2025Q4: 2,485,638 shares; 2026Q1: 2,360,638 shares; 2026Q2: 2,075,639 shares 2,075,639$9.65M0.57%-284,999Timeline
XLOXILIO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 664,021 shares; 2026Q2: 664,021 shares 664,021$6.36M0.38%0Timeline
UPBUPSTREAM BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: not reported; 2024Q4: 2,295,322 shares; 2025Q1: 2,295,322 shares; 2025Q2: 2,439,538 shares; 2025Q3: 2,439,538 shares; 2025Q4: 1,329,544 shares; 2026Q1: 867,211 shares; 2026Q2: 600,949 shares 600,949$4.16M0.25%-266,262Timeline
NAMSWNEWAMSTERDAM PHARMA COMPANYQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q3: 100,000 shares; 2024Q4: 100,000 shares; 2025Q1: 100,000 shares; 2025Q2: 100,000 shares; 2025Q3: 100,000 shares; 2025Q4: 99,999 shares; 2026Q1: 99,999 shares; 2026Q2: 99,999 shares 99,999$2.14M0.13%0Timeline

Sold out in Q2 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
CNTACENTESSA PHARMACEUTICALS PLC635,000$25.2Mshares

How Q2 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001193125-26-350470 base2026-08-14acceptance time not in the bulk data set

Filings

Every filing of this filer: 13F reports and notices, the 13D and 13G it filed or is a reporting person of, and Forms 3, 4 and 5 it reported as an owner.

FilingSubjectFiledAcceptedIngested
13F-HR 0001193125-26-350470 Quarter ended 2026-06-302026-08-14acceptance time not in the bulk data set
13F-HR 0001193125-26-226961 Quarter ended 2026-03-312026-05-15acceptance time not in the bulk data set
13F-HR 0001193125-26-054833 Quarter ended 2025-12-312026-02-17acceptance time not in the bulk data set
13F-HR 0001193125-25-283094 Quarter ended 2025-09-302025-11-14acceptance time not in the bulk data set
13F-HR 0000950123-25-008312 Quarter ended 2025-06-302025-08-14acceptance time not in the bulk data set
13F-HR 0000950123-25-005465 Quarter ended 2025-03-312025-05-15acceptance time not in the bulk data set
13F-HR 0000950123-25-002317 Quarter ended 2024-12-312025-02-14acceptance time not in the bulk data set
13F-HR 0000950123-24-011417 Quarter ended 2024-09-302024-11-14acceptance time not in the bulk data set
13F-HR 0000950123-24-007830 Quarter ended 2024-06-302024-08-12acceptance time not in the bulk data set
13F-HR 0000950123-24-005471 Quarter ended 2024-03-312024-05-15acceptance time not in the bulk data set
13F-HR 0000950123-24-001898 Quarter ended 2023-12-312024-02-13acceptance time not in the bulk data set
13F-HR 0000950123-23-010856 Quarter ended 2023-09-302023-11-14acceptance time not in the bulk data set
13F-HR 0000950123-23-008184 Quarter ended 2023-06-302023-08-14acceptance time not in the bulk data set
13F-HR 0000950123-23-005321 Quarter ended 2023-03-312023-05-15acceptance time not in the bulk data set
13F-HR 0000950123-23-002178 Quarter ended 2022-12-312023-02-14acceptance time not in the bulk data set
13F-HR 0000950123-22-012270 Quarter ended 2022-09-302022-11-14acceptance time not in the bulk data set
13F-HR 0000950123-22-009430 Quarter ended 2022-06-302022-08-15acceptance time not in the bulk data set
13F-HR 0000950123-22-006412 Quarter ended 2022-03-312022-05-16acceptance time not in the bulk data set
13F-HR 0000950123-22-002471 Quarter ended 2021-12-312022-02-14acceptance time not in the bulk data set
13F-HR 0000950123-21-015534 Quarter ended 2021-09-302021-11-15acceptance time not in the bulk data set
13F-HR 0000950123-21-011522 Quarter ended 2021-06-302021-08-16acceptance time not in the bulk data set
13F-HR 0000950123-21-006704 Quarter ended 2021-03-312021-05-17acceptance time not in the bulk data set
13F-HR 0000950123-21-002146 Quarter ended 2020-12-312021-02-16acceptance time not in the bulk data set
13F-HR 0000950123-20-011923 Quarter ended 2020-09-302020-11-16acceptance time not in the bulk data set
13F-HR 0000950123-20-008777 Quarter ended 2020-06-302020-08-14acceptance time not in the bulk data set
13F-HR 0000950123-20-005061 Quarter ended 2020-03-312020-05-15acceptance time not in the bulk data set
13F-HR 0000950123-20-002136 Quarter ended 2019-12-312020-02-14acceptance time not in the bulk data set
13F-HR 0000950123-19-011059 Quarter ended 2019-09-302019-11-14acceptance time not in the bulk data set
13F-HR 0000950123-19-007984 Quarter ended 2019-06-302019-08-14acceptance time not in the bulk data set
13F-HR 0000950123-19-005099 Quarter ended 2019-03-312019-05-15acceptance time not in the bulk data set
13F-HR 0000950123-19-001853 Quarter ended 2018-12-312019-02-14acceptance time not in the bulk data set
13F-HR 0000950123-18-011520 Quarter ended 2018-09-302018-11-14acceptance time not in the bulk data set
13F-HR 0000950123-18-008490 Quarter ended 2018-06-302018-08-14acceptance time not in the bulk data set
13F-HR 0000950123-18-005392 Quarter ended 2018-03-312018-05-15acceptance time not in the bulk data set
13F-HR 0000950123-18-001950 Quarter ended 2017-12-312018-02-14acceptance time not in the bulk data set